Phase II Trial of RAD001 in Refractory Colorectal Cancer
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
Single center open-label study of an oral agent (RAD001) in subjects with metastatic
colorectal cancer refractory to at least 2 standard chemo/biologic regimens.